Free tool
FAERS Monitor: Tembexa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214460 or its brand name (Tembexa, Brincidofovir). Reports on generic versions are filed under their own applications.
Reports
139
Serious
114
82% of reports
Hospitalization
42
Death reported
57
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use40
- acute kidney injury27
- adenovirus infection15
- drug ineffective14
- drug resistance12
- graft versus host disease in gastrointestinal tract11
- hypotension11
- immune reconstitution inflammatory syndrome11
- multiple organ dysfunction syndrome11
- condition aggravated9
- cytomegalovirus infection9
- pancytopenia9
- respiratory failure9
- acute graft versus host disease in skin8
- diarrhoea8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 17 |
| 2017 | 12 |
| 2018 | 9 |
| 2019 | 23 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 19 |
| 2024 | 22 |
| 2025 | 11 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,020 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| adenovirus infectionSignal | 15 | 786.7 | 487.1 | 10,943 |
| graft versus host disease in gastrointestinal tractSignal | 11 | 786.3 | 445.2 | 7,820 |
| acute graft versus host disease in skinSignal | 8 | 439.2 | 223.9 | 3,065 |
| immune reconstitution inflammatory syndromeSignal | 11 | 334.8 | 189.7 | 3,328 |
| cytomegalovirus infectionSignal | 9 | 82.0 | 43.6 | 641 |
| drug resistanceSignal | 12 | 70.7 | 41.2 | 757 |
| multiple organ dysfunction syndromeSignal | 11 | 58.8 | 33.3 | 569 |
| acute kidney injurySignal | 27 | 26.7 | 19.0 | 647 |
| pancytopeniaSignal | 9 | 24.4 | 13.0 | 179 |
| respiratory failureSignal | 9 | 18.7 | 9.9 | 134 |
| hypotensionSignal | 11 | 8.3 | 4.7 | 64 |
| off label useSignal | 40 | 6.9 | 5.3 | 205 |
| condition aggravatedSignal | 9 | 4.5 | 2.4 | 21 |
| diarrhoea | 8 | 1.9 | 1.0 | 3 |
| drug ineffective | 14 | 1.6 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.